Levels of Inflammatory Markers in the Treatment of Stroke—An SPS3 Ancillary Study (LIMITS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00579306
Recruitment Status : Completed
First Posted : December 24, 2007
Last Update Posted : July 24, 2017
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Mitchell S Elkind, Columbia University

Brief Summary:
The goals of this trial are to determine the prognostic significance of an elevated level of inflammatory blood markers in people who have experienced small subcortical strokes and who are enrolled in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.

Condition or disease
Hypertension Stroke

Detailed Description:

Inflammation is increasingly recognized as playing a central role in atherosclerosis and coronary artery disease. And, peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these risk markers—which have the potential to be modified—to prognosis after ischemic stroke is less clear.

The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study will address questions about the role of inflammatory markers in secondary stroke prevention in a cost-effective manner using the well-established framework of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. The SPS3 trial is an ongoing Phase 3, multicenter secondary stroke prevention trial that focuses on preventing stroke recurrence in people with small vessel ischemic stroke, or lacunes.

The overall purpose of the LIMITS study is to determine if serum levels of inflammatory markers—such as hsCRP, serum amyloid A (SAA), CD40 ligand (CD40L), and monocyte chemoattractant protein-1 (MCP-1)—predict recurrent stroke and other vascular events among people with a history of small artery ischemic stroke. The project will also determine if these markers predict which people will respond best to dual antiplatelet therapy with clopidogrel and aspirin.

The specific aims of LIMITS are to determine if hsCRP, SAA, CD40L, and MCP-1 levels are independent risk factors for recurrent ischemic stroke, and for recurrent ischemic stroke, myocardial infarction, and death in participants in the SPS3 trial after adjusting for demographic and traditional stroke risk factors, and other treatments, using a prospective cohort of people with small subcortical strokes from the SPS3 trial. LIMITS also aims to compare the efficacy of dual versus single antiplatelet therapy among participant groups with and without elevated baseline inflammatory marker levels for the outcome of a.) recurrent stroke, and b.) recurrent ischemic stroke, myocardial infarction, or death.

Study Type : Observational
Actual Enrollment : 1244 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Levels of Inflammatory Markers in the Treatment of Stroke
Actual Study Start Date : June 2005
Actual Primary Completion Date : April 2012
Actual Study Completion Date : July 2012

SPS3 patient cohort
All SPS3 patients who participate in Baseline and 1-Year F/U blood draw

Primary Outcome Measures :
  1. Percentage of participants with recurrent stroke [ Time Frame: Up to 5 years ]
    Participants with recurrence of any stroke during follow-up, including ischemic (an acute localized ischemic lesion in the brain not attributable to central nervous system infection, tumor, demyelinating, or degenerative neurologic diseases due to an occlusive vascular disorder) and hemorrhagic (acute extravasation of blood into the parenchyma of the central nervous system or subarachnoid space).

Secondary Outcome Measures :
  1. Percentage of participants developing major cognitive decline [ Time Frame: Up to 5 years ]

    Documentation of a major cognitive decline during follow-up. This is a clinical decline in cognitive function manifested by functional deterioration/behavioral changes that are not associated with a clinical stroke event.

    Criteria: Both A and B must be met:

    A) A drop in the Cognitive Abilities Screening Instrument (CASI) score of > 10 points since study entry and sustained on repeat testing in approximately one month B) Associated behavioral changes and/or function

Biospecimen Retention:   Samples Without DNA
blood serum (ancillary study)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with a symptomatic small vessel stroke within prior 6 month and enrolled in SPS3

Inclusion Criteria:

  • Patient must be randomized within 6 months of qualifying small subcortical stroke (S3) or subcortical TIA
  • One of the following lacunar syndromes: PMH; pure sensory stroke; sensorimotor stroke; ataxic hemiparesis; dysarthria; hemiballism; PMH with facial sparing, horizontal gaze palsy, contralateral III palsy, contralateral VI palsy; Ataxia with contralateral III palsy; pure dysarthria
  • Absence of cortical dysfunction (aphasia, apraxia, agnosia)
  • No ipsilateral cervical carotid stenosis (>= 50%) if S3 is hemispheric
  • No major-risk cardioembolic sources requiring anti-coagulation
  • MRI evidence of S3 that is >=2.0 cm in diameter if DWI/bright lesion on FLAIR/T2 or <=1.5cm hypointense lesion on FLAIR/T1, corresponding to the qualifying event (required for all brainstem events) OR multiple S3 in cerebral hemispheres of <=1.5cm hypointense lesions on FLAIR/T1 AND absence of cortical stroke and large subcortical stroke.

Exclusion Criteria:

  • Disabling stroke (Ranking Scale >= 4)
  • Prior hemorrhagic stroke
  • Age <30 years
  • High risk of bleeding (recurrent GI or GU bleeding, active peptic ulcer disease, etc)
  • Need for long-term use of anticoagulants or other antiplatelet agents.
  • Prior cortical or retinal stroke / TIA
  • Prior ipsilateral carotid endarterectomy if hemispheric S3
  • Impaired renal function: GFR<40 cc/min
  • Intolerance/contraindication to aspirin or clopidogrel
  • Adjusted Folstein MMSE <24
  • Medical contraindication to MRI
  • Pregnancy or child-bearing potential without contraception
  • Other specific causes of stroke (e.g. dissection, vasculitis, drug abuse)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00579306

  Hide Study Locations
United States, Alabama
University of South Alabama
Mobile, Alabama, United States, 36617
United States, Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States, 85259
University of Arizona Collage of Medicine
Tucson, Arizona, United States, 85724
United States, California
University of California, San Diego Medical Center
La Jolla, California, United States, 92093-0979
Sutter Neuroscience Institute
Sacramento, California, United States, 95816
United States, Florida
Melbourne Internal Medicine Associates
Melbourne, Florida, United States, 32901
University of Miami
Miami, Florida, United States, 33136
United States, Iowa
Mercy Medical Center
Des Moines, Iowa, United States, 50314
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
United States, Massachusetts
Boston University Medical Center
Boston, Massachusetts, United States, 02118
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48201
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Minnesota
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55404
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
United States, Missouri
St. Louis University
Saint Louis, Missouri, United States, 63104
St. John's Mercy Medical Center
Saint Louis, Missouri, United States, 63141
United States, New Jersey
Cooper University Hospital,
Camden, New Jersey, United States, 08103
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Rochester General Hospital
Rochester, New York, United States, 14621
University of Rochester Medical Center
Rochester, New York, United States, 14642
Helen Hayes Hospital
West Haverstraw, New York, United States, 10993
United States, North Carolina
Wake Forest University Medical Center
Winston-Salem, North Carolina, United States, 27157-1078
United States, Ohio
University Hospitals of Cleveland, Case Western Reserve University,Case Western Neurological Unit, 11100 Euclid Avenue, Lakeside 5508
Cleveland, Ohio, United States, 44106
Metro Health Medical Center
Cleveland, Ohio, United States, 44109
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Texas
University of Texas South Western Medical Center
Dallas, Texas, United States, 75390-8897
The Methodist Hospital
Houston, Texas, United States, 77030
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
United States, Wisconsin
Marshfield Clinic Research Foundation
Marshfield, Wisconsin, United States, 54449
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Canada, Nova Scotia
Dalhousie University Center for Clinical Research
Halifax, Nova Scotia, Canada, B3H 4V7
Canada, Quebec
Hospital Charles LeMoyne Centre de recherché
Greenfield Park, Quebec, Canada, J4V 2H1
McGill University Health Center
Montreal, Quebec, Canada, H3G 1A4
Pontificia Universidad Catolica de Chile
Santiago, Chile
Hospital Naval Almirante Nef
Viña del Mar, Chile, 2530116
Hospital-Clinica Kennedy
Guayaquil, Ecuador
Universidad Autonoma de Guadalajara
Guadalajara, JAL, Mexico, 44280
Instituto Nacional de Neurología y Neurocirugía
Mexico, Mexico City, Mexico, 14269
Hospital Nacional Alberto Sabogal
Lima, Peru, 41
Hospital Clinico Universitario de Santiago de Compostela
Barcelona, Spain, 08907
Hospital del Mar
Barcelona, Spain, 08907
Hospital del Sagrat Cor
Barcelona, Spain, 08907
Hospital Dr. Josep Trueta
Barcelona, Spain, 08907
Hospital Germans Trias i Pujol,
Barcelona, Spain, 08907
Hospital Universitario de Bellvitge, Spain
Barcelona, Spain, 08907
Sponsors and Collaborators
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Mitchell S. Elkind, MD, MS, FAAN Columbia University
Principal Investigator: Oscar Benavente, MD UTHSC San Antonio (SPS3 Principal Investigator)
Principal Investigator: Robert Hart, MD UTHSC San Antonio (SPS3 Principal Investigator)

Responsible Party: Mitchell S Elkind, Associate Professor of Neurology and Epidemiology (in the Sergievsy Center), Columbia University Identifier: NCT00579306     History of Changes
Other Study ID Numbers: AAAB1202
R01NS050724 ( U.S. NIH Grant/Contract )
First Posted: December 24, 2007    Key Record Dates
Last Update Posted: July 24, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Mitchell S Elkind, Columbia University:
cerebrovascular accident

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases